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Accumulating evidence suggests that self-renewal and diﬀerentiation capabilities reside only in a subpopulation of tumor cells,
termed cancer stem cells (CSCs), whereas the remaining tumor cell population lacks the ability to initiate tumor development or
support continued tumor growth. In head and neck squamous cell carcinoma (HNSCC), as with other malignancies, cancer stem
cells have been increasingly shown to have an integral role in tumor initiation, disease progression, metastasis and treatment
resistance. In this paper we summarize the current knowledge of the role of CSCs in HNSCC and discuss the therapeutic
implications and future directions of this ﬁeld.
1.Introduction
Head and neck squamous cell carcinoma (HNSCC) ranks
sixth worldwide for cancer-related mortality, with an esti-
mated 500000 new cases diagnosed yearly [1]. For the past
several decades the mainstay of treatment for HNSCC has
been surgery and external beam radiation. More recent
clinical trials have demonstrated the beneﬁt of combining
chemotherapy and radiation for advanced stage disease,
leading to modest improvements in treatment outcomes
[1–5]. Despite this recent improvement, the increase in
overall survival has been nominal and cancer recurrence
and treatment failures continue to occur in a signiﬁcant
percentage of patients. The biology underpinning why some
tumors respond favorably to treatment and others do not is
largely unknown.
Over the last 15 years, advances in tumor biology have
led to the discovery that many cancers, including HNSCC,
appear to be supported by cells with stem-like properties.
Studies in a wide variety of malignancies have demonstrated
that only a distinct subpopulation of tumor cells, termed
cancer stem cells (CSCs), contain the ability to undergo
self-renewal and diﬀerentiation (properties of normal stem
cells) and hence have the ability to initiate tumorigenesis
and support ongoing tumor growth. Furthermore, it appears
that, like their normal stem cell counterparts, CSCs have
increased resistance to standard cytotoxic therapies. These
ﬁndings have coalesced into the cancer stem cell theory of
tumorigenesis, which has remarkable implications on our
understanding of tumor initiation, disease progression, and
treatment response. Here we review the basics of the cancer
stem cell theory as it applies to HNSCC.
2. Emergence of the Cancer Stem Cell Theory
The cellular and molecular requirements for initiation of
tumorigenesis are a series of mutations resulting in the
acquisition of replication and growth-factor independence,
resistance to growth-inhibitory signals, tissue invasion, and
metastasis [6]. The mechanisms underlying these mutations
have been extensively interrogated; however a unifying
“model of tumorigenesis” remains to be completely elu-
cidated. Tumors have long been recognized to consist of2 Journal of Oncology
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Figure 1: CSC Theory. (a) Origin of CSC. CSC may originate
from endogenous stem cells (SC) or reprogramming of the transit
amplifying (TA) or diﬀerentiated (Diﬀ) cell population. (b) The
CSC theory proposes a tumor cell hierarchy with the CSC at the
apex. Only CSCs are able to give rise to new tumors and provide
support for ongoing tumor growth (Green: CSC, Red: Transit
amplifying population, Pink: diﬀerentiated cell population).
a heterogeneous population of cells diﬀering in proliferative
capacity, histologic and immunophenotypic appearance,
and tumorigenic potential. Traditionally, this heterogeneity
has been hypothesized to be the result of the stochastic
accumulation of numerous and varied individual mutations
and microenvironmental signals that provide a selective
advantage to certain tumor cells. Over the last several years
however, a new hypothesis has emerged suggesting that
tumor heterogeneity is supported by a stem cell hierarchy.
The cancer stem cell hypothesis postulates that tumor het-
erogeneity with regards to initiation, progression, response
to therapy, and metastasis is the result of mutations which
either render a normal somatic tissue stem cell cancerous,
or cause a cancer cell to become stem cell-like [7]. This
mutated CSC is then capable of giving rise both to additional
CSCs and to a variety of more diﬀerentiated and functionally
divergent cancer cells, much like a normal somatic tissue
stem cell. Unlike in the traditional stochastic tumorigenesis
model, the CSC model proposes that tumorigenicity resides
in only a small subpopulation of cancer cells and that these
cells, rather than the bulk of the tumor, are responsible for
tumor initiation and growth (Figure 1).
As with normal somatic stem cells, CSCs are deﬁned by
their ability to self-renew and to give rise to a heterogeneous
population of tumor cells. This population of tumor cells
consists of rapidly dividing cells (similar to the transient
amplifying (TA) cell population in normal tissue) as well
as additional CSCs and more diﬀerentiated tumor cells.
In addition to their replicative capacity, CSCs, like their
somatic counterparts, are also more resistant to the eﬀects
of cytotoxic chemotherapies and radiation damage [8–
16]. Deﬁning this stem cell hierarchy and the complex
relationship between these cell populations has critical
implications, not only for the understanding of the biology
of tumor initiation and progression, but also for prognosis
and treatment.
CSCs were ﬁrst experimentally deﬁned in hematopoietic
malignancies by John Dick and colleagues in 1994 [17].
Transplantation of a deﬁned subpopulation of human
acute myeloid leukemia (AML) cells (CD34hi CD38low) into
immunodeﬁcientmicewasnotonlyabletorecapitulateAML
but it was phenotypically and pathologically similar to the
patient’s original leukemia. In contrast, the remaining cell
populations (CD34low and CD34hi CD38hi) failed to give rise
to new leukemia cells.
In the 15 years since the identiﬁcation of the leukemic
stem cell, a number of investigators have identiﬁed CSCs in
solid malignancies. In 2003, Michael Clarke and colleagues
were the ﬁrst to identify a CSC population in a solid tumor.
A subpopulation of CD44hi CD24low breast cancer cells were
able to recapitulate phenotypically heterogeneous breast
cancers at very low limiting dilutions in mouse xenograft
experiments [18]. Since then a number of other groups have
deﬁned CSC populations in other epithelial malignancies
including colorectal, prostate, lung, brain, and HNSCC [19–
23]. The identiﬁcation of the cell population responsible
for initiating tumorigenesis has signiﬁcant implications for
the prognosis and treatment of cancer. At present, cytotoxic
chemotherapies target the rapidly cycling cells of the tumor
andresultinimpressivereductionintumorsize,butleavethe
largely chemotherapy-resistant CSCs untouched [10, 15, 24–
26]. Additionally, both in vitro assays and in vivo monitoring
for eﬀectiveness of new experimental cancer therapies are
based on reduction in cell number or tumor size. It is
therefore theoretically possible that therapies which result
in tumor cell death, as currently assayed, will not have any
signiﬁcant eﬀect on the CSC and will therefore not result
in long-term disease control or eradication. The ability of
the CSC to produce phenotypically diverse tumor cells may
also contribute to increased metastatic potential with new
mutations selecting for migratory and invasive properties of
the tumor.
3.Endogenous HeadandNeckStemCellsand
theOriginof CancerStemCells
The origin of the cancer-initiating cell has long been
presumed to be the normal endogenous tissue stem cell.
This is based upon their similar behaviors and the notion
that only accumulated mutations within a long-lived cell
could ultimately result in tumorigenesis. In colorectal cancer
there is a strong correlation between induced loss of
the Wnt signaling molecule APC in a putative stem cell
population and the formation of benign intestinal polyps
[27], providing evidence that intestinal cancers can arise
from a progenitor population. However, it is possible that
accumulation of genetic mutations within a diﬀerentiated or
progenitor cell can allow expression of stem cell behavior,
and that this may provide an alternative source of CSCs. For
example, oncogene expression driven from myeloid-speciﬁcJournal of Oncology 3
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Figure 2:CSCIdentiﬁcation.(a)TumorsphereformationbyCSCs.
Diﬀerentiated tumor cells (pink) are unable to give rise to new
clonally derived tumor spheres, whereas CSCs (green) give rise
to new tumor spheres, (b) Tumor subpopulations are identiﬁed
through diﬀering mechanisms, including cell surface markers,
aldehyde dehydrogenase activity, side population and are isolated
with ﬂuorescence-activated cell sorting (FACS). Xenotransplanta-
tion assays in immunocompromised mice demonstrate tumori-
genic, self-renewing and diﬀerentiation properties of putative CSC
population.
promoters resulted in generation of mouse models of human
leukemias [28, 29]. Despite focused examination, the origin
of the CSC remains controversial.
With the primary focus on identifying CSC markers
in HNSCC, little is known about the identity or the
location of the normal endogenous stem cell or the stem
cell microenvironment. Several studies have examined the
putative HNSCC CSC marker CD44 in normal head and
neck epithelia with diﬀering conclusions. In one study,
isolated CD44hi normal oral keratinocytes were shown to
exhibit a G2-block associated with apoptosis resistance, a
potential stem cell feature [30], suggesting that CD44 is
likely expressed in normal head and neck epithelial stem
cells. However, a subsequent study demonstrated that 60%–
95% of the normal epithelia express CD44 (or 60%–80%
the splice variant CD44 v6), far too many cells to be
considered tissue stem cells. While CD44 populations may
indeed harbor a subpopulation encompassing stem cells,
by itself it does not appear to be an adequate stem cell
markerfornormaloralmucosa[31].Theheadandneckstem
cell identity and niche is clearly underexplored, however,
key insights from the skin [32, 33], airway mucosa [34]
and esophagus [35] may guide future investigations into
elucidation of this stem cell population.
4. Cancer Stem Cell Identiﬁcation
Methods for the identiﬁcation of CSCs in solid malignancies
mirror those strategies employed to diﬀerentiate normal
stem cells from their diﬀerentiated progeny. These include
the eﬄux of vital dyes by multidrug transporters, the
enzymatic activity of aldehyde dehydrogenase, colony and
sphere-forming assays utilizing speciﬁc culture conditions
andthemostwidelyusedmethod—theexpressionofspeciﬁc
cell surface antigens known to enrich for stem cells. Once
the subpopulation of tumor cells has been identiﬁed and
isolated, functional characterization through quantitative
xenotransplantation assays, the gold-standard for identiﬁca-
tion of CSCs, are used to assess the tumorigenicity and self-
renewing potential of the putative CSC population in vivo
(Figure 2).
4.1. Surface Antigens. By far the most common method of
identifying CSCs has relied on the expression of speciﬁc cell-
surface antigens that enrich for cells with CSC properties.
Many of these antigens were initially targeted because of
their known expression on endogenous stem cells. While a
multitude of studies have identiﬁed CSC markers across a
variety of solid malignancies, relatively few of these markers
have been studied in HNSCC.
4.1.1. CD133. A pentaspan transmembrane glycoprotein
localizedoncellmembraneprotrusions[36,37],isaputative
CSC marker for a number of epithelial malignancies includ-
ing brain, prostate, colorectal, and lung [38, 39]. In HNSCC
cell lines, CD133hi cells display increased clonogenicity,
tumor sphere formation and tumorigenicity in xenograft
models when compared to their CD133low counterparts [26,
40, 41]. While CD133 expression has been noted in primary
human HNSCC tumors, quantitative xenotransplantation
assays utilizing CD133+hi cells from fresh tumors has yet
to be performed. Given the artiﬁcial environment of cell
culture, these ﬁndings will need to be substantiated using
primarytumorsamplesbeforeanydeﬁnitiveconclusionscan
be made about the usefulness of CD133 as a CSC marker in
HNSCC.
4.1.2. CD44. One of the most well-recognized CSC markers,
is a large cell surface glycoprotein that is involved in
cell adhesion and migration. It is a known receptor for
hyaluronic acid and interacts with other ligands such as
matrixmetalloproteases[42,43].Initiallyidentiﬁedasasolid
malignancy CSC marker in breast cancer [18], Prince et al.
demonstrated that CD44 expression could also be used to
isolate a tumor subpopulation with increased tumorigenicity
in HNSCC [23]. In their study they were able to show that as
few as 5,000CD44hi HNSCC cells could form a tumor when
transplanted into the ﬂank of immunocompromised mice,
whereashigherconcentrationsofCD44low cellsfailedtoform
tumors. Additionally, these tumors recapitulated the original
tumor’s cellular heterogeneity and could be serially passaged,
characteristics that deﬁne CSCs.
Although CD44 expression enriches for cells with CSC
properties, the relatively high number of cells required for
tumor formation as compared with known CSC populations
from other epithelial malignancies raises questions about
whether CD44 expression alone is suﬃcient for isolation of
a pure CSC population. For instance, in breast cancer, as few
as100CSCsinjectedintothemammaryfatpadsofimmuno-
compromised mice generated tumors [18]. It is important to
note that in the Prince study, two-thirds of HNSCC samples
were initially passaged through immunocompromised mice
to generate a suﬃcient number of tumor cells for cell
sorting, which has the potential for altering native CSC4 Journal of Oncology
expression patterns. Using primary human tumor samples
as well as utilizing a more natural host microenvironment
through an orthotopic xenograft model [44]m i g h tr e d u c e
the number of cells needed to generate tumors. However, it
is likely that expression of multiple cell surface markers or
the combination of marker expression with functional assays
will be needed to further enrich the CSC population.
4.2. Aldehyde Dehydrogenase Activity. Aldehyde dehydroge-
nase (ALDH) is an intracellular enzyme normally present
in the liver. Its known functions include the conversion of
retinol to retinoic acids and the oxidation of toxic aldehyde
metabolites, like those formed during alcohol metabolism
and with certain chemotherapeutics such as cyclophos-
phamide and cisplatin [45–47]. ALDH activity is known to
enrich hematopoetic stem/progenitor cells [48]a n dm o r e
recently has been shown to enrich cells with increased stem-
like properties in solid malignancies [49–52]. Chen et al.
showed that ALDH activity correlated with disease staging in
HNSCC and that higher enzymatic activity correlated with
expression of epithelial-to-mesenchymal transition (EMT)
genes as well as enriching cells with CSC properties [53].
In addition, ALDH activity appears to enrich for CSCs in
HNSCC to a higher degree than that currently provided
by cell sorting based on surface antigen expression. Clay
et al. demonstrated that as few as 500ALDHhi cancer cells
could give rise to new HNSCC tumors when transplanted
into immunocompromised mice, tenfold fewer cells than
isolation by CD44 positivity. Most of the ALDHhi cells were
alsoCD44high,suggestingthatALDHactivitydeﬁnesasubset
of HNSCC CD44high cells with increased tumorigenicity
[54].
4.3. Side Population. Hoechst 33342 is a ﬂuorescent DNA-
binding dye that preferentially binds to A-T rich regions. It is
actively pumped out of cells by members of the ATP-binding
cassette (ABC) transporter superfamily. Once stained with
Hoechst dye, cells can be sorted by ﬂuorescent-activated cell
sorting (FACS) based upon the activity level of these mul-
tidrug transporters. Originally noted to enrich bone marrow
for long-term hematopoetic stem cells [55], this method
has also been used to identify cells within solid tumors
with increased tumorigenicity [21, 56, 57]. Side population
( S P )c e l l sf r o mo r a ls q u a m o u sc e l lc a r c i n o m ah a v eb e e n
shown to have increased clonogenicity and tumorigenicity in
xenotransplantation assays [25, 58]. Furthermore, HNSCC
SP cells displayed higher expression of known stem cell
related genes—Oct4, CK19, BMI-1 and CD44—and lower
expression of involucrin and CK13, genes associated with a
diﬀerentiated status [58].
4.4. Tumor Sphere Formation. Under serum-free culture
conditions CSCs can be maintained in an undiﬀerentiated
state, and when driven toward proliferation by the addition
of growth factors, form clonally derived aggregates of cells
termed tumor spheres [22]. The ability of CSCs—but not
the remaining tumor bulk—to form tumor spheres has been
used extensively in neural tumors to identify populations
enriched for CSCs. In HNSCC, these spheres have been
shown to be enriched for stem markers, including CD44hi
[59], Oct-4, Nanog, Nestin, and CD133hi [26, 60], as well as
exhibiting increased tumorigenicity in orthotopic xenografts
[60].
5. Cancer Stem Cells and Disease Progression
While there exists signiﬁcant data deﬁning the presence of
CSCs within a variety of tumor types and many aspects of
the cell and molecular biology of CSC have been elucidated,
the manner in which this unique cell population inﬂuences
clinical disease progression remains unclear. Given that
metastases can be formed from implantation of a single
tumor cell [61], it seems likely that CSCs, as the progenitor
of all tumor cell types, would be responsible for metastatic
spread. Central to the CSC hypothesis is the presence of
a unique stem cell “niche” or environment necessary to
support the growth of stem cells [62]. It has been shown that
a premetastatic niche is established by the attraction of bone
marrow derived cells to the future site of metastases by the
secretion of factors from cancer cells and that blocking the
creation of this premetastatic niche prevents metastases [63].
What these secreted factors are and whether they are secreted
by CSCs or one of their progeny remains an open question;
however, creation of this niche, possibly for the arrival of
CSCs to form a metastasis, appears to be a crucial step in
metastatic spread.
The strongest evidence that CSCs are responsible for
metastases comes not in HNSCC but in colorectal cancer.
In this tumor, a unique CSC population that is CD26hi
appears to be tightly linked with metastases [64]. Not only
are CD26hi cells found in both primary and metastatic
tumors, but the presence of CD26hi cells in the primary
tumor predicted future development of metastases. In a
mouse xenograft study, CD26hi CSCs implanted into the
cecal wall of a nude mouse formed a tumor in the colon
as well as liver metastases, while CD26low CSCs formed a
tumor at the site of implantation without developing liver
metastases. Similarly, injection of CD26hi CSCs into the
portal vein led to liver metastases, while similar injection of
CD26low CSCs did not. Thus, these CD26hi CSCs appear to
be the cells responsible for metastatic spread in this tumor
population.
Another stem cell marker, CD44, has also been impli-
cated in metastatic spread and disease progression in
HNSCC,althoughtheCD44storyismorecomplex.Recently,
three diﬀerent isoforms, CD44 v3, v6, and v10, have been
shown to be associated with progression and metastasis of
HNSCC [65]. Increased CD44 v3 expression in primary
tumors was associated with lymph node metastasis, while
CD44 v10 expression was associated with distant metastasis
and CD44 v6 expression was associated with perineural
spread. In cell culture, blockade of these CD44 isoforms with
isoform-speciﬁc antibodies inhibited cellular proliferation,
with the greatest inhibition seen with blockade of CD44
v6. Finally, increased expression of CD44 v6 and v10 was
associatedwithshorteneddisease-freesurvival.Thesestudies
suggest that alteration in CSC phenotype through variationJournal of Oncology 5
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Figure 3: CSC Theory and Treatment Response. (a) Current
chemotherapy and radiation treatment regimens with broad
cytotoxic eﬀects kill the bulk of diﬀerentiated tumor cells with
preferential sparring of resistant CSCs, giving apparent volumetric
reductionoftumorbutsubsequentrecurrence.(b)Targetedtherapy
preferentially kills CSC leaving nonrenewing cells with eventual
tumor death.
in CD44 isoform expression may alter the interaction of
CSCs with the surrounding microenvironment. This may
allow CSCs to more readily invade surrounding tissues or
metastasize, thereby promoting disease progression.
6. Cancer Stem Cells and Treatment Response
Aside from providing a model of disease progression and
metastasis, CSCs have important implications regarding
cancer treatment. While current chemotherapy and radia-
tion treatment for HNSCC are focused on indiscriminate
cytoreduction, the CSC hypothesis suggests that only by
eliminating CSCs can cancer be treated eﬀectively (Figure 3).
However, there is substantial evidence that CSCs have
inherent drug and radiation resistance, rendering most
conventional therapies ineﬀective and explaining tumor
recurrence despite signiﬁcant reductions in tumor volume.
Bydeﬁnition,stemcellsmustdividefrequentlyandthushave
highly stringent mechanisms to prevent and rapidly correct
DNAdamage.InthecaseofCSCs,thereisevidencethatthese
enhanced DNA protection and damage repair pathways lead
to signiﬁcant resistance to radiation and chemotherapy.
The presence of a CSC population has thus far been
implicated in radioresistance of multiple tumor types. For
example, glioblastoma tumors that recur after radiation
have been found to be enriched in CD133hi CSCs [9].
Furthermore, this radioresistance of CD133hi CSCs appears
to be mediated through enhanced repair of DNA damage
via the Chk1 and Chk2 kinases [9] and through enhanced
cell longevity via the histone deacetylase SirT1 [11]. Similar
results have been seen in a murine model of breast cancer,
which showed that CSCs have substantially lower amounts
of reactive oxygen species, leading to radioresistance [13].
HNSCC CSCs also demonstrated enhanced radioresistance
in murine models that could be reduced by knockdown
of the transcriptional repressor Bmi-1 [66]. However, the
radioresistance of CSCs may not only depend on factors
intrinsic to the CSC, but may also be driven by the
unique CSC microenvironment. Cell cultures of CSCs from
glioblastoma, pancreatic, breast, and colorectal carcinoma
have been reported to have similar radiosensitivity to cell
cultures that are not enriched for CSCs [8, 16].
In addition to radioresistance, CSCs also appear to
mediate chemoresistance in multiple tumor types. There is
evidence for chemoresistance of CSCs in lung [10], pancre-
atic [15], and breast carcinoma [12]. In HNSCC, CSCs were
made more chemosensitive via knockdown of Bmi-1 [66].
Moreover, knockdown of CD44 increased the sensitivity of
HNSCC cells to cisplatin, indicating that this CSC marker
may be involved in meditating the response of these cells
to chemotherapy. Other mechanisms of chemoresistance,
such as drug eﬄux pumps, have been postulated but not
yet identiﬁed in HNSCC. Future studies will be needed
to further deﬁne resistance mechanisms in HNSCC CSCs
to improve therapy and possibly prevent tumor spread or
recurrence.
7.Prospectus
While the CSC theory is revolutionizing our understanding
of tumor biology, many things remain to be elucidated
regarding the role of CSCs in HNSCC. For starters, addi-
tionalmarkersthatenrichCSCsinotherepithelialmalignan-
cies need to be evaluated in HNSCC. Only a limited number
of CSC markers have been examined in HNSCC, and for
each of these the reported number of marker-positive cells
needed for tumor formation is signiﬁcantly higher than what
has been reported for other solid malignancies. It is clear
that further puriﬁcation of the CSC population in HNSCC
is necessary.
To date, only a few studies have used primary human
HNSCC tissue for CSC marker identiﬁcation [23, 54].
Prince et al. used primary tumor specimens in one-third
of their samples, with the remaining two-thirds passaged
initially through nude mice to generate a larger tissue sample
prior to cell isolation [23]. Although this methodology
has been used in other seminal studies for CSC marker
identiﬁcation [18] and was considered state of the-art at the
time, increasing knowledge of the inﬂuence of the tumor
microenvironment on the CSC clearly suggests avoidance of
additional cell manipulation is preferred. In fact, in their
follow-up study evaluating ALDH activity as a CSC marker
in HNSCC all samples were from primary tumors [54].
Future studies should follow this example and concentrate
on marker identiﬁcation using primary tumor samples.
Use of intermediate steps involving an artiﬁcial microenvi-
ronment has the ability to distort the naturally occurring
CSC marker expression pattern. For similar reasons marker
identiﬁcation on HNSCC cell lines should be interpreted
with caution.
It is becoming more clear that the cellular heirarchy
deﬁned by the CSC theory is likely more complex than
originally realized. Single marker identiﬁcation may not be
suﬃcient to identify a pure CSC population. In fact, as
demonstrated in glioblastoma, CSCs can express or lack the
traditional CSC marker CD133 yet still retain the functional
characteristics that deﬁne a CSC [67]. It may be that6 Journal of Oncology
expression of CSC markers evolves with disease progression
and the accumulation of additional mutations or changes
in response to therapy. It is possible that several distinct
populations of CSCs with diﬀering markers exist within a
single tumor and that a combination of the clonal evolution
and CSC models of tumorigenesis may be more appropriate
than either alone to explain the behavior of some tumors.
Additional work is also needed in deﬁning the expression
patterns of CSC markers in the endogenous setting. Little
is known, especially in the head and neck, about the
endogenous expression patterns of putative CSC markers.
Further, it is unknown if the stem cell niche of head and
neckmucosaissimilartothatofcutaneousskinorifregional
diﬀerences in CSC marker expression exist between subsites
of the upper aerodigestive tract. Clearly an understanding of
normal head and neck mucosal CSC marker expression is
critical if attempts are to be made to selectively target CSCs
as part of a treatment regimen for HNSCC.
To date, most studies have focused on the identiﬁcation
of tumor cell populations enriched for cells with stem-like
properties. We have little understanding of the signiﬁcance
of the markers used to identify these cells—whether they
are simply markers of convenience or whether they have
functional signiﬁcance remains unknown. Examining the
role these molecules may play in the tumorigenic, metastatic,
and treatment resistance properties of CSCs is certainly a
logical step on our way to discovering the mechanisms by
whichCSCsdiﬀerfromtheremainingtumorcellpopulation.
The CSC theory oﬀers an intriguing insight into why
currently available therapies for head and neck cancer so
often fail. While increasing evidence suggests that CSCs
display increased resistance to multiple treatment paradigms
inclusive of chemotherapy and radiation, the exact mecha-
nisms by which they do this are incompletely understood.
Focused research on mechanisms of treatment resistance in
CSCs and whether they can be overcome will prove equally
important as eﬀorts to improve CSC identiﬁcation.
Increasing our knowledge of the diﬀerences between
CSCs, their diﬀerentiated progeny and normal endogenous
stem cells, will translate into our ability to understand the
seemingly complex cellular hierarchy in tumors. Ultimately
an understanding of CSCs has the potential to identify novel
targets for therapy and impact patient care.
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